FAST COO Ryan Fischer Named 2026 Co-Chair of EveryLife Community Congress
Ryan Fischer, FAST’s COO, has been named a 2026 Community Congress Patient Advocacy Group Co-Chair, leading regulatory science efforts for the rare disease community.
Turning Possibility Into Progress: The Rush F.A.S.T. Center for Translational Research Opens in Chicago
FAST and Rush University Medical Center opened a $5 million translational research center, a groundbreaking hub built to accelerate Angelman syndrome trials and train specialists.
Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board
FAST welcomes Dr. Nick France, a rare disease drug development leader from Alexion, AstraZeneca Rare Disease, to its Board of Directors, bringing two decades of biopharmaceutical and gene therapy expertise.
Introducing the Angelman Syndrome Global Community Advisory Board (CAB)
The Angelman Syndrome Alliance introduces its Global Community Advisory Board (CAB), a EURORDIS-trained group of parent advocates from around the world dedicated to representing family voices in Angelman syndrome research, policy, and advocacy.
2024 Global Science Summit Recap
The 17th Global Science Summit gathered over 1,000 attendees from 55 countries, spotlighting major progress across FAST’s research pillars and multiple advancing clinical trials.
FAST announces establishment of associated drug development accelerator AS²Bio
FAST launches AS²Bio, a drug development accelerator building an integrated ecosystem to advance gene therapy, CRISPR, and stem cell programs for Angelman syndrome and beyond.